U.S. patent application number 16/142977 was filed with the patent office on 2019-05-02 for upar targeting peptide for use in peroperative optical imaging of invasive cancer.
This patent application is currently assigned to RIGSHOSPITALET. The applicant listed for this patent is RIGSHOSPITALET. Invention is credited to Andreas KJAER, Morten PERSSON.
Application Number | 20190125903 16/142977 |
Document ID | / |
Family ID | 59093318 |
Filed Date | 2019-05-02 |
![](/patent/app/20190125903/US20190125903A1-20190502-C00001.png)
![](/patent/app/20190125903/US20190125903A1-20190502-C00002.png)
![](/patent/app/20190125903/US20190125903A1-20190502-D00001.png)
![](/patent/app/20190125903/US20190125903A1-20190502-D00002.png)
![](/patent/app/20190125903/US20190125903A1-20190502-D00003.png)
![](/patent/app/20190125903/US20190125903A1-20190502-D00004.png)
![](/patent/app/20190125903/US20190125903A1-20190502-D00005.png)
United States Patent
Application |
20190125903 |
Kind Code |
A1 |
KJAER; Andreas ; et
al. |
May 2, 2019 |
UPAR TARGETING PEPTIDE FOR USE IN PEROPERATIVE OPTICAL IMAGING OF
INVASIVE CANCER
Abstract
There is provided a novel conjugate that binds to the cell
surface receptor uPA (uPAR). The conjugate is based on a
fluorescence-labeled peptide useful as a diagnostic probe to the
surfaces of cells expressing uPAR. The conjugate is capable of
carrying a suitable detectable and imageable label that will allow
qualitative detection and also quantitation of uPAR levels in vitro
and in vivo. This renders the surgical resection of tumors more
optimal.
Inventors: |
KJAER; Andreas;
(Frederiksberg, DK) ; PERSSON; Morten;
(Copenhagen, DK) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
RIGSHOSPITALET |
Copenhagen |
|
DK |
|
|
Assignee: |
RIGSHOSPITALET
Copenhagen
DK
|
Family ID: |
59093318 |
Appl. No.: |
16/142977 |
Filed: |
September 26, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15512276 |
Mar 17, 2017 |
10111969 |
|
|
PCT/DK2015/050261 |
Sep 3, 2015 |
|
|
|
16142977 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 49/0032 20130101;
A61K 49/0056 20130101; A61K 49/0034 20130101 |
International
Class: |
A61K 49/00 20060101
A61K049/00 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 17, 2014 |
DK |
PA 2014 70573 |
Claims
1. A fluorophor labelled u PAR-targeting peptide conjugate having
the formula:
X-Y-(D-Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-
-(Tyr)-(Leu)-(Trp)-(Ser) wherein, X represents imageable moiety
capable of detection either directly or indirectly in a optical
imaging procedure, and Y represents a spacer, a biomodifier or is
absent
2. A fluorophor labelled uPAR-targeting peptide conjugate as
claimed in claim 1 of the formula: ##STR00002## and
pharmaceutically acceptable salts thereof.
3. The compound of claim 1 for use in fluorescence guided surgical
resection of tumours.
4. The compound of claim for use according to claim 3, wherein the
compound is administered to a subject in a dose of 0.1-1000 mg per
person.
5. The compound of claim 1 for peroperative optical imaging of
cancer.
6. A pharmaceutical composition for optical imaging of cancer,
wherein the composition comprises a compound of claim 1 together
with at least one pharmaceutically acceptable carrier or
excipient.
7. The pharmaceutical composition of claim 6, wherein the
concentration of the compound is 0.1-1000 mg per dosage unit.
8. Use of a compound of claim 1 for the manufacture of a diagnostic
agent for use in a method of optical imaging of cancer involving
administration of said compound to a subject and generation of an
image of at least part of said subject.
9. Use according to claim 8, wherein the compound is administered
to the subject in a dose of 0.1-1000 mg per subject.
10. A method of optical imaging of cancer of a subject involving
administering a compound of claim 1 to the subject and generating
an optical image of at least a part of the subject to which said
compound has distributed.
11. Method of claim 10, wherein the compound of claim 1 is
administered to the subject in a dose of 0.1-1000 mg per subject.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a novel conjugate that
binds to the cell surface receptor urokinase-type plasminogen
activator receptor (uPAR). More specifically the conjugate is based
on a fluorescence-labeled peptide useful as a diagnostic probe to
the surfaces of cells expressing uPAR. The conjugate of the
invention is capable of carrying a suitable detectable and
imageable label that will allow for clear tumor delineation both in
vitro and in vivo. This renders the surgical resection of tumors
more optimal.
BACKGROUND OF THE INVENTION
[0002] When performing cancer surgery with intent of radically
remove cancer and metastases, delineation of active tumour is a
major challenge and accordingly, either cancer tissue is left
behind with poor prognosis or to ensure radical surgery,
unnecessary extensive surgery is performed with removal of
substantial amounts of healthy tissue.
[0003] Developments in the area of improved methods for cancer
resection have in many years been stagnant. A surgeon's finest task
is still to differentiate between healthy and diseased tissue under
white light illumination. This can in many cases be difficult due
to hidden areas of diseased tissue. In cancer treatment the best
prognosis comes with complete removal of the cancerous tissue [1,
2]. Today the gold standard for assuring optimal resection is to
take histological samples in the tumor bed and test for positive
tumour margins. Several studies have shown this to be both
inaccurate and time consuming.
[0004] Intraoperative optical imaging is a new emerging technique
that allows the surgeon to differentiate between healthy and
diseased tissue with help from a targeted optical probe [3, 4].
Near Infrared (NIR) florescence-imaging is a newer technique that
can be used in intraoperative optical imaging. NIR fluorescence has
some advantages compared to other widely used fluorophors with
lower wavelength maxima. Tissue penetration is one of the forces of
NIR fluorophors (NIRFs. Moreover, tissue autoflourescence is
minimised in the NIR range and therefore enhance the tumour to
background ratio needed for intraoperative imaging. These
properties make NIRFs ideal for intraoperative surgery.
[0005] In neurosurgical oncology, fluorescence to guide surgery of
high-grade glioblastoma has already been investigated [1]. The
current fluorescence guided surgery (FGS) use ALA induces PpIX
fluorescence which utilise the PpIX produced in all mammal cells.
However a significant higher production of PpIX is found in tumour
cells (14-17 pogue et all 2010). Even though this system delineates
the tumour with success, the system still has its drawbacks.
Therefore, a clear clinical need for more specific targeting with
NIRFs has evolved.
[0006] Urokinase-type plasminogen activator receptor (uPAR) is
frequently over expressed in many cancer types. Expression of uPAR
is associated with metastatic disease and poor prognosis and the
receptor is often located in excess in the invasive front of the
tumour.
[0007] This makes uPAR ideal as a targeted probe for intraoperative
optical imaging. A well validated uPAR targeted peptide AE105 has
been used extensively in PET imaging for targeting uPAR previously
by our group [5-8].
[0008] Recently, optical imaging using fluorescence was introduced
to help delineating tumors. One example is indo-cyanin green (ICG)
that to some extent unspecifically leaks out into tumors due to
vascularization and leaky vessels. However, the unspecific nature
of the methods limits its value.
[0009] Handgraaf et al [15] recognize that ICG is a non-targeted
dye and its chemical structure does not allow conjugation to tumor
specific ligands.
[0010] WO2014/086364 and WO2013/167130 disclose the use of
radionuclide-labelled uPAR binding peptides for PET-imaging of
cancer diseases. Such compounds were coupled via a chelating agent
to a radionuclide.
[0011] Hence, there is a need for an improved imaging probe for
guided surgery.
SUMMARY OF THE INVENTION
[0012] The present inventors have surprisingly conjugated AE105
with indocyanine green (ICG). Due to the relatively large size and
high hydrophobicity of ICG, two glutamic acid was used as a linker
between AE105 and ICG (FIG. 1), thus providing minimal interference
between AE105 and ICG. This novel fluorescent probe
AE105-Glu-Glu-ICG has unexpectedly shown both in vitro and in vivo
potential for use in fluorescent-guided cancer resection. It is to
be noted that the prior art does not focus on the fluorophor
labelled uPAR-targeting peptide conjugate although the prior art
discloses radionuclide-labelled uPAR binding peptides.
[0013] Accordingly, the novel probe AE105-Glu-Glu-ICG enables a
whole new concept where targeted optical imaging of the invasive
cancer cells uses the proteolytic system receptor uPAR as a target.
The major advantages are that it is tumour specific and that it
particularly accumulates in the invasive front of cancers.
Accordingly, it is clearly indicating where the active border of a
tumour is relative to surrounding healthy tissue. In this way, the
surgeon can exactly see where the tumour stops and remove only the
tumour. If no tissue lightening up is left behind the cancer was
successfully removed.
[0014] In accordance with the present invention there is therefore
provided a novel fluorophor labelled uPAR-targeting peptide
conjugate having the formula:
X-Y-(D-Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)-(Tyr)-(L-
eu)-(Trp)-(Ser)
[0015] wherein,
[0016] X represents imageable moiety capable of detection either
directly or indirectly in a optical imaging procedure, and
[0017] Y represents a spacer, a biomodifier or is absent.
[0018] Particularly preferred are conjugates having the formula
##STR00001##
[0019] The compounds are preferably for use in fluorescence guided
surgical resection of tumours. In this respect the compounds are
administered to a subject in a dose of 0.1-100 mg per person. In
such an application it is very suitable for peroperative optical
imaging of cancer.
[0020] The present invention also provides a pharmaceutical
composition for optical imaging of cancer, wherein the composition
comprises a compound of the invention together with at least one
pharmaceutically acceptable carrier or excipient. The dose of the
compound is preferably 0.1-100 mg per person.
[0021] The invention also encompasses the use of the compound for
the manufacture of a diagnostic agent for use in a method of
optical imaging of metastatic cancer involving administration of
said compound to a subject and generation of an image of at least
part of said subject.
[0022] In a further aspect there is provided a method of optical
imaging of cancer of a subject involving administering the compound
of the present invention to the subject and generating an optical
image of at least a part of the subject to which said compound has
distributed.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] FIG. 1 shows the structural formula of the compound of the
present invention with indications of peptide and fluorophor
part.
[0024] FIG. 2 shows staining experiments with rabbit-anti-uPAR.
[0025] FIG. 3 shows photographs of tumor scans with the compound of
the invention and with ICG.
[0026] FIG. 4 shows quantitative analysis of the tumor and
background uptake.
[0027] FIG. 5 shows photographs of tumor scans with the compound of
the invention using Fluorobeam.RTM..
DETAILED DESCRIPTION OF THE INVENTION
[0028] Concerning the synthesis of the peptides used in the present
invention reference is made to U.S. Pat. No. 7,026,282.
[0029] The peptide/chelate conjugates of the invention are labelled
by reacting the conjugate with radionuclide, e.g. as a metal salt,
preferably water soluble. The reaction is carried out by known
methods in the art.
Example
[0030] The peptide AE105 (Asp-Cha-Phe-Ser-Arg-Tyr-Leu-Trp-Ser-OH)
was synthesized by standard solid-phase peptide chemistry. The
peptide AE105 was conjugated to ICG
(4-(2-((1E,3E,5E,7Z)-7-(3(5-carboxypentyl)-1,1-dimethyl-1H-benzo[e]indol--
2(3H)-ydlidene)hepta-1,3,5-trienyl)-1,1dimethyl-1H-benzo[e]indolium-3-yl)b-
utane-1-sulfonate) with two glutamic acids as linker
(ICG-Glu-Glu-AE105); see FIG. 1. The probe has a final weight of
2197.55 g/mol. For in vivo injection ICG-Glu-Glu-AE105 was
dissolved in (2-hydroxypropyl)-.beta.-cyclodextrin with 2%
DSMO.
[0031] Cell Lines
[0032] Human glioblastoma cell line U87MG was purchased from the
American Type Culture Collection and culture media was obtained
from Invitrogen. U87MG was cultured in DMEM added 10% FBS and 1%
PenStrep. When the cells reached 70-80% confluency the cells were
harvested.
[0033] All animal experiments were performed under a protocol
approved by the Animal Research Committee of the Danish Ministry of
Justice. 5*10.sup.6 U87MG cells were suspended in 200 ul PBS and
inoculated on both flanks of the mouse. When the tumours reached an
appropriate size the mice were imaged with AE105-Glu-Glu-ICG.
[0034] Flowcytometry
[0035] After harvesting of cells were washed in buffer and stained
with either an in-house produced antibody (3 .mu.g/ml), IgG isotype
(3 g/ml; 14-4714 eBioscience) or blank control for 1 hr in
4.degree. C. on a shaking table. The cells were washed 3 times with
buffer and then stained with a secondary antibody
(goat-anti-mouse-PE 1/500) for 30 min in 4.degree. C. on a shaking
table. The result was analysed on the BD FACSCanto cell
analyser.
[0036] ELISA Assay
[0037] Tumours were homogenised and a suspension containing the
tumor lysate were stored at -80.degree. C. The plate was coated
with an anti uPAR antibody R2 (3 .mu.g/ml) overnight at 4.degree.
C. After this incubation 2% BSA was added for 5 min and the plate
was washed with buffer. uPAR standard (10 ng/ml) or tumor lysate
(diluted 1:20) was added and incubated for 2 hr in RT and washed
with buffer. A primary antibody (rabbit-anti-uPAR, 1 .mu.g/ml) was
added to the well and incubated for 30 min in RT and washed. A
secondary HRP conjugated anti-rabbit antibody was added (diluted
1:2500) and incubated for 30 min in RT and washed. The bound HRP
conjugated antibody was quantified by adding 4 OPD tablets (Dako
#S2045) in 12 ml water and 10 .mu.l H.sub.2O.sub.2. The reaction
was stopped with 1M H.sub.2SO.sub.4 when the proper coloration of
the well was present. An ELISA reader was used to analyze the plate
at 490 nm and 650 nm as reference.
[0038] Optical Imaging
[0039] The mice were injected with 10 nmol of AE105-Glu-Glu-ICG or
ICG i.v., and imaged 15 hr post injection. Before scan the mice
were anaesthetized with 2% isofluran and positioned in a prone
position. For imaging the IVIS Lumina XR and the acquisition
software Living Image were used. The excitation filter was set to
710 nm and the emission filter was set in the ICG position.
Acquisition was set to auto-settings to achieve the best
acquisition as possible.
[0040] After imaging with IVIS Lumina XR the mouse were moved to a
Fluobeam setup and imaged with appropriate acquisition time.
[0041] The TBR values were calculated by drawing a ROI over each
tumor and place the background ROI in an area with constant
background signal.
[0042] Results
[0043] In the production of the novel uPAR targeted fluorescence
probe of the present invention two glutamic acids were introduced
as linkers to partly reduce a potential interaction between ICG and
the binding affinity of AE105 toward uPAR. The results indeed
revealed a reduction in the binding affinity towards purified uPAR
for ICG-Glu-Glu-AE105 (IC.sub.50.apprxeq.80 nM) compared to AE105
(IC.sub.50.apprxeq.10 nM), however the probe surprisingly retained
sufficient affinity for guided surgical procedures.
[0044] Before any in vivo experiments were initiated, with U87MG
cancer cells the expression of uPAR was measured in vitro by
flowcytometry. The staining with rabbit-anti-uPAR showed a clear
rightshift in fluorescence compared to the control, thus confirming
high level of uPAR expression (FIG. 2a). The expression of uPAR was
also investigated on histological samples from tumors grown for 5
weeks in vivo using IHC staining (FIG. 2b). An intense staining for
uPAR expression was found, thus confirming the result from
flowcytometry.
[0045] A group of mice were scanned 15 hr post injection with
ICG-Glu-Glu-AE105 in the IVIS Lumina XR. A high uptake in the tumor
was observed (FIG. 3) and quantitative analysis of the tumor and
background uptake, resulted in a tumor-to-background (TBR) ratio of
3.52.+-.0.167 (n=10) (FIG. 4a). The max radiance for the tumors was
in the range 3.43E+08.+-.0.34E+08 radiance efficiency.
[0046] Next, a group of mice were imaged with only ICG in order to
validate the specificity of the new probe. No specific uptake was
seen in the tumor. TBR for ICG was 1.04.+-.0.04 (n=10) (The max
radiance for the tumors were in the range 7.51E+06.+-.3.13E+05).
All tumors from both groups of mice were subsequently resected
after the last scan and the uPAR expression in the tumor lysate was
analysed. uPAR expression level was identical in each group
(3.19.+-.0.59 for ICG and 2.64.+-.0.28 for ICG-Glu-Glu-AE105) (FIG.
4a).
[0047] Finally, to delineate the translational use of this method,
the group of mice injected with ICG-Glu-Glu-AE105 was also imaged
with the clinically approved camera Fluobeam.RTM. (FIG. 5). Clear
tumor identification was possible due to high uptake of
ICG-Glu-Glu-AE105 as seen in FIG. 5. This imaging modality gave
similar TBR (3.58.+-.0.29.) as the IVIS Lumina XR and thus confirms
the translational potential of ICG-Glu-Glu-AE105.
[0048] Data Interpretation
[0049] Intraoperative optical imaging with NIR is a new emerging
technique that can help surgeons remove solid tumours with higher
accuracy and decrease the number of patient with positive margins.
In this study, the newly synthesised probe ICG-Glu-Glu-AE105 was
characterized in vitro and in vivo in a human glioblastoma
xenograft mouse model.
[0050] Many designs of optical probes have been constructed.
Several groups have investigated probes targeting the EGFR
receptor[9], integrin .alpha..sub.v.beta..sub.3 [10] and HER1 and
HER2 [11]. Numerous probes are based on antibodies as targeting
vectors because of the ease of conjugating them to fluorophors and
the well-known high affinity for the target. However, a number of
limitations in using antibodies for in vivo optical imaging are
present. The size of an antibody influences the pharmacological
profile, and result in a long plasma half-life which again results
in a high background and decrease the potential TBR value. An
acceptable TBR value is therefore only achievable 1-3 days after
injection [9, 12], thus limiting the clinical usefulness and
thereby the translation potential. If smaller peptides are used an
optimal imaging timepoint can get as low as 3-6 hours after
injection as a result of faster clearing time. In the present
study, a scan time 15 hrs post injection was found to be optimal
for the peptide-based probe, thus providing a clinical useful
application where a patient would be injected in the evening before
planned surgery the next day.
[0051] The conjugated fluorophor is also an important choice to
make. There exist numerous fluorophors in the NIR window with
different properties. It was chosen to use ICG since it is the most
often-used fluorophor because of its long history in angiographies,
It is FDA approved and has a well-established safety profile, thus
paving the way for a more easy clinical translation. The
fluorescent properties of ICG has been passed by other upcoming
fluorophors such as IRDye 800CW. This newer developed fluorophor
exhibit features as higher brightness, easier conjugation and
hydrophilicity. Especially the hydrophobicity of ICG seems to be an
important feature considering the reduction in binding affinity
found in this study due to conjugation of ICG, where both the size
and high hydrophobicity seems to be responsible for this
observation. One potential solution to this observation could be to
use a longer linker and/or a more hydrophilic linker such as PEG.
This approach has been done with success by others [13]. However,
the limited safety profile and no clinical data for IRDye 800CW in
contrast to ICG, makes any clinical translation difficult in near
future. Translation of a new probe from preclinical studies to the
clinical bed is with an approved fluorophor as ICG more
advantageous. However the linker is not only for protection of the
peptide. Several studies [13] have shown that conjugation of ICG to
an antibody decrease the fluorescent signal from ICG. A comparison
of ICG and ICG-Glu-Glu-AE105 showed a 2-fold decrease in
fluorescence intensity for the conjugated probe (data not shown). A
group have though shown that quenching of ICG is eliminated when
the probe interact with cells [11], due to internalization and
degradation of the conjugated vector. The ICG molecule is released
and de-quenched. This property can be exploited in vivo where the
non-internalized circulating probe has lower fluorescence intensity
than the targeted internalized probe. ICG have primarily been used
for delineating malignant glioblastomas. However, ICG has only been
used in excessive doses were macroscopic colouration of the tissue
have delineated the tumour and the fluorescent properties have been
neglected. Further, this delineation of the tumour is most likely a
result of the EPR effect and not a tumour specific
accumulation.
[0052] Several targets for optical imaging in cancer detection have
been investigated and both endogenous and exogenous fluorophors has
shown great potential for clinical translation. Conversion of 5-ALA
to PpIX, an endogenous fluorescent process, has been shown to occur
in excess in glioblastomas and have reached clinical studies with
convincing results. An advantage uPAR, as target, holds over 5-ALA
is the information given regarding the tumors phenotype. uPAR has
been correlated with a poor prognosis and aggressive metastatic
behavior. Further uPAR have shown to be expressed in the invasive
front of the tumor and in the surrounding stroma. This makes uPAR
an ideal target for NIR intraoperative optical resection of solid
tumors. In addition the receptor need to be over expressed on the
surface of the cancer cells. This has been confirmed by
flowcytometry for the glioblastoma cell line used in this human
xenograft model.
[0053] The main aim was to develop a targeted ICG probe, with high
affinity and specificity towards uPAR and high in vivo stability.
Results from this study have shown that the newly developed probe
ICG-Glu-Glu-AE105 possesses all these properties. Conjugated to the
clinical approved fluorophor ICG the use of this probe in
intra-operative imaging has a high clinical translation
potential.
REFERENCES
[0054] 1. Pogue B W, Gibbs-Strauss S L, Valdes P A, et al. Review
of Neurosurgical Fluorescence Imaging Methodologies. IEEE J Select
Topics Quantum Electron 16:493-505. doi: 10.1109/JSTQE.2009.2034541
[0055] 2. Mushawah MD Catherine M Appleton MD Amy E Cyr MD William
E Gillanders MD Rebecca L Aft MD PhD Timothy J Eberlein MD Feng Gao
PhD Julie A Margenthaler MD Al JABF, Mushawah MD Al F, MD CMA, et
al. (2012) Positive margin rates following breast-conserving
surgery for stage I-Ill breast cancer: palpable versus nonpalpable
tumors. Journal of Surgical Research 177:109-115. doi:
10.1016/j.jss.2012.03.045 [0056] 3. Nguyen Q T, Tsien R Y (2013)
Fluorescence-guided surgery with live molecular navigation--a new
cutting edge. Nature Publishing Group 1-10. doi: 10.1038/nrc3566
[0057] 4. Vahrmeijer A L, Hutteman M, van der Vorst J R, et al.
(2013) Image-guided cancer surgery using near-infrared
fluorescence. Nature Publishing Group 10:507-518. doi:
10.1038/nrclinonc.2013.123 [0058] 5. Persson M, Madsen J,
Ostergaard S, et al. (2012) Quantitative PET of human
urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105:
implications for visualizing cancer invasion. Journal of Nuclear
Medicine 53:138-145. doi: 10.2967/jnumed.110.083386 [0059] 6.
Persson M, Madsen J, Ostergaard S, et al. (2012) 68Ga-labeling and
in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated
peptide for PET imaging of invasive cancers. Nuclear Medicine and
Biology 39:560-569. doi: 10.1016/j.nucmedbio.2011.10.011 [0060] 7.
Persson M, Liu H, Madsen J, et al. (2013) First 18F-labeled ligand
for PET imaging of uPAR: In vivo studies in human prostate cancer
xenografts. Nuclear Medicine and Biology 40:618-624. doi:
10.1016/j.nucmedbio.2013.03.001 [0061] 8. Li Z B, Niu G, Wang H, et
al. (2008) Imaging of Urokinase-Type Plasminogen Activator Receptor
Expression Using a 64Cu-Labeled Linear Peptide Antagonist by
microPET. Clinical Cancer Research 14:4758-4766. doi:
10.1158/1078-0432.CCR-07-4434 [0062] 9. Day K E, Sweeny L, Kulbersh
B, et al. (2013) Preclinical Comparison of Near-Infrared-Labeled
Cetuximab and Panitumumab for Optical Imaging of Head and Neck
Squamous Cell Carcinoma. Mol Imaging Biol. doi:
10.1007/s11307-013-0652-9 [0063] 10. Hutteman M, Mieog J S D, van
der Vorst J R, et al. (2011) Intraoperative near-infrared
fluorescence imaging of colorectal metastases targeting integrin
αvβ3 expression in a syngeneic rat model. YEJSO 37:252-257. doi:
10.1016/j.ejso.2010.12.014 [0064] 11. Ogawa M, Kosaka N, Choyke P
L, Kobayashi H (2009) In vivo Molecular Imaging of Cancer with a
Quenching Near-Infrared Fluorescent Probe Using Conjugates of
Monoclonal Antibodies and Indocyanine Green. Cancer Res
69:1268-1272. doi: 10. 1158/0008-5472.CA N-08-3116 [0065] 12. Ogawa
M, Regino C A S, Seidel J, et al. (2009) Dual-Modality Molecular
Imaging Using Antibodies Labeled with Activatable Fluorescence and
a Radionuclide for Specific and Quantitative Targeted Cancer
Detection. Bioconjugate Chem 20:2177-2184. doi: 10.1021/bc900362k
[0066] 13. Sano K, Nakajima T, Miyazaki K, et al. (2013) Short
PEG-Linkers Improve the Performance of Targeted, Activatable
Monoclonal Antibody-Indocyanine Green Optical Imaging Probes.
Bioconjugate Chem 24:811-816. doi: 10.1021/bc400050k [0067] 14. Li
Y, Rey-Dios R, Roberts D W, et al. (2014) Peer-Review Reports.
World Neurosurgery 1-11. doi: 10.1016/j.wneu.2013.06.014 [0068] 15.
Henricus J. M. Handgraaf, Floris P. R. Verbeek, et al. (2014)
Real-time near-infrared fluorescence guided surgery in gynecologic
oncology: A review of the current state of the art. Gynecologic
Oncology http://dx.doi.org/10.1016/j.ygyno.2014.08.005
* * * * *
References